Therapeutic strategies for neurodegenerative disorders have commonly targeted individual
aspects of the disease pathogenesis to little success. Neurodegenerative diseases …

Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …

Activation of microglia by classical inflammatory mediators can convert astrocytes into a
neurotoxic A1 phenotype in a variety of neurological diseases,. Development of agents that …

Despite an ever-growing prevalence and increasing economic burden of Alzheimer's
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …

Background Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has
neuroprotective effects in preclinical models of Parkinson's disease. We investigated …

Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion, glucose
concentrations, lipid metabolism, gut motility, appetite and body weight, and immune …

Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone mainly secreted from intestinal L
cells in response to nutrient ingestion. GLP‐1 has beneficial effects for glucose homeostasis …

The glucagon-like peptide (GLP)-1 receptor (GLP-1R) is a class BG protein–coupled
receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secreted from three …